Search

Your search keyword '"Alsina, Mercé"' showing total 20 results
Start Over Author "Alsina, Mercé" Publication Year Range Last 50 years
20 results on '"Alsina, Mercé"'

1. Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain

Author

Daudén, Esteban, de Lima, Glauber Pacelli Gomes, Armesto, Susana, Herrera-Acosta, Enrique, Vidal, David, Villarasa, Eva, Rivera, Raquel, de la Cueva, Pablo, Martorell, Antonio, Ballesca, Ferran, Belinchón, Isabel, Carretero, Gregorio, Rodríguez, Lourdes, Romero-Maté, Alberto, Pujol-Montcusí, Josep, Salgado, Laura, Sahuquillo-Torralba, Antonio, Coto-Segura, Pablo, Baniandrés, Ofelia, Feltes, Rosa, Alsina, Mercé, and Llamas-Velasco, Mar

Published
2021
Full Text
View/download PDF

2. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry

Author

Pérez Zafrilla, Beatriz, Muñoz-Santos, Carlos, Mendiola-Fernández, Victoria, Sánchez Roldán, Cristina, Ruiz-Genao, Diana, Echeverría, Begoña, Galiano Mejías, Sagrario, Dávila-Seijo, Paula, Dauden, Esteban, Descalzo, M.A., Carretero, Gregorio, Carrascosa, José-Manuel, Vanaclocha, Francisco, Gómez-García, Francisco-José, De la Cueva-Dobao, Pablo, Herrera-Ceballos, Enrique, Belinchón, Isabel, López-Estebaranz, José-Luis, Alsina, Merce, Sánchez-Carazo, José-Luis, Ferrán, Marta, Torrado, Rosa, Ferrandiz, Carlos, Rivera, Raquel, Llamas, Mar, Jiménez-Puya, Rafael, and García-Doval, Ignacio

Published
2017
Full Text
View/download PDF

3. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis

Author

Daudén, Esteban, Llamas-Velasco, Mar, Santamaría, Cristina, Carretero, Gregorio, Vilar-Alejo, Jaime, Madrid Álvarez, Blanca, Rivera, Raquel, García-Donoso, Carmen, Gomis, Ma del Mar Onteniente, Batista Cabrera, Diana, Ferrándiz, Carlos, Manuel Carrascosa, José, Ballescá, Ferrán, de la Cueva, Pablo, Molina Mejías, Patricia, Belinchón, Isabel, García Giner, Carlos, Perez, Alfred, Gómez-García, Fran J., Herrera-Ceballos, Enrique, Herrera-Acosta, Enrique, Martínez-García, Eliseo, Sánchez, Cristina, López-Estebaranz, José Luis, Patricia Ruiz-Genao, Diana, García Zamora, Elena, Ferrán Farrés, Marta, Alsina, Mercè, Riera, Josep, Pedregosa Fauste, Sara, Baniandrés, Ofelia, María Nieto Benito, Lula, Molina, Desiree, Sánchez-Carazo, José Luis, Sahuquillo-Torralba, Antonio, Botella-Estrada, Rafael, Pujol Marco, Conrad, Chaparro Aguilera, Natalia, Massó López, Verónica, Rodríguez Fernández-Freire, Lourdes, Mateu Puchades, Almudena, Santos, Sergio, Sáez Belló, Marina, Flórez Menéndez, Ángeles, Salgado, Laura, González Sixto, Beatriz, Abalde, Ma Teresa, Vilanova, Lucia, Perez Mariño, Alexandra, Eiris, Noemí, Prieto Marcos, Vicenta, García-Doval, Ignacio, Ángel Descalzo Gallego, Miguel, de Vega Martínez, Marina, Baniandrés-Rodríguez, Ofelia, Carrascosa, José Manuel, Nieto-Benito, Lula María, Fernández-Freire, Lourdes Rodríguez, Ruiz-Genao, Diana Patricia, Riera-Monroig, Josep, and Descalzo Gallego, Miguel Ángel

Published
2021
Full Text
View/download PDF

6. Risk of Serious Adverse Events Associated With Biologic and Nonbiologic Psoriasis Systemic Therapy: Patients Ineligible vs Eligible for Randomized Controlled Trials

Author

Garcia-Doval, Ignacio, Carretero, Gregorio, Vanaclocha, Francisco, Ferrandiz, Carlos, Daudén, Esteban, Sánchez-Carazo, Jose-Luis, Alsina, Mercé, Herrera-Ceballos, Enrique, Gómez-García, Francisco-José, Ferrán, Marta, López-Estebaranz, Jose-Luis, Hernanz, Jose-Manuel, Belinchón-Romero, Isabel, Vilar-Alejo, Jaime, Rivera, Raquel, Carrascosa, Jose-Manuel, and Carazo, Cristina

Published
2012
Full Text
View/download PDF

7. The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study

Author

Sahuquillo-Torralba, Antonio, primary, Carretero, Gregorio, additional, Rivera, Raquel, additional, Ferrándiz, Carlos, additional, Daudén-Tello, Esteban, additional, de la Cueva, Pablo, additional, Gómez-García, Francisco José, additional, Belinchón, Isabel, additional, Herrera-Acosta, Enrique, additional, Ruiz-Genao, Diana, additional, Ferrán, Marta, additional, Alsina, Mercé, additional, Sánchez-Carazo, Jose Luís, additional, Baniandrés, Ofelia, additional, Fernández-Freire, Lourdes Rodríguez, additional, Vilar, Jaime, additional, García-Donoso, Carmen, additional, Carrascosa, Jose Manuel, additional, Llamas-Velasco, Mar, additional, Herrera-Ceballos, Enrique, additional, López-Estebaranz, José Luis, additional, Pujol-Marco, Conrad, additional, Descalzo, Miguel Ángel, additional, and García-Doval, Ignacio, additional

Published
2020
Full Text
View/download PDF

9. Histologic evidence that mast cells contribute to local tissue inflammation in peripheral spondyloarthritis by regulating interleukin-17A content

Author

Chen, Sijia, primary, Noordenbos, Troy, additional, Blijdorp, Iris, additional, van Mens, Leonieke, additional, Ambarus, Carmen A, additional, Vogels, Esther, additional, te Velde, Anje, additional, Alsina, Mercé, additional, Cañete, Juan D, additional, Yeremenko, Nataliya, additional, and Baeten, Dominique, additional

Published
2018
Full Text
View/download PDF

10. Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort.

Author

HERNÁNDEZ-FERNÁNDEZ, Carlos Pelayo, CARRETERO, Gregorio, RIVERA, Raquel, FERRÁNDIZ, Carlos, DAUDÉN, Esteban, DE LA CUEVA, Pablo, BELINCHÓN, Isabel, GÓMEZ-GARCÍA, Francisco Javier, HERRERA-ACOSTA, Enrique, RUIZ-GENAO, Diana P., FERRÁN, MARTA, ALSINA, Mercé, BANIANDRÉS-RODRÍGUEZ, Ofelia, SÁNCHEZ-CARAZO, Jose Luis, BOTELLA-ESTRADA, Rafael, SAHUQUILLO-TORRALBA, Antonio, RODRIGUEZ, Lourdes, VILAR-ALEJO, Jaime, GARCÍA-DONOSO, Carmen, and CARRASCOSA, Jose M.

Subjects
PSORIASIS treatment, GENDER, PSORIASIS, TREATMENT effectiveness, DRUG prescribing
Abstract

The effect of sex on systemic therapy for psoriasis has not been well studied. The aim of this study was to analyse a large multicentre Spanish cohort of 2,881 patients with psoriasis (58.3% males), followed from January 2008 to November 2018, to determine whether sex influences prescription, effectiveness of therapy, and the risk of adverse events. The results show that women are more likely than men to be prescribed biologics. There were no differences between men and women in effectiveness of therapy, measured in terms of drug survival. Women were more likely to develop adverse events, but the difference in risk was small and does not justify different management. Study limitations include residual confounding and the use of drug survival as a proxy for effectiveness. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

11. Histologic evidence that mast cells contribute to local tissue inflammation in peripheral spondyloarthritis by regulating interleukin-17A content.

Author

Chen, Sijia, Noordenbos, Troy, Blijdorp, Iris, Mens, Leonieke van, Ambarus, Carmen A, Vogels, Esther, Velde, Anje te, Alsina, Mercé, Cañete, Juan D, Yeremenko, Nataliya, and Baeten, Dominique

Subjects
THERAPEUTIC use of monoclonal antibodies, ANKYLOSING spondylitis, CELLULAR signal transduction, DERMIS, IMMUNOHISTOCHEMISTRY, INFLAMMATION, INFLAMMATORY bowel diseases, INTERLEUKINS, MAST cells, MUCOUS membranes, SYNOVIAL membranes, GENE expression profiling
Abstract

Objectives Synovial mast cells contain IL-17A, a key driver of tissue inflammation in SpA. A recent in vitro study showed that tissue-derived mast cells can capture and release exogenous IL-17A. The present study aimed to investigate if this mechanism could contribute to tissue inflammation in SpA. Methods Potential activation of mast cells by IL-17A was assessed by gene expression analysis of the Laboratory of Allergic Diseases 2 (LAD2) mast cell line. The presence of IL-17A-positive mast cells was assessed by immunohistochemistry in synovial tissue obtained before and after secukinumab treatment, as well as in skin and gut tissues from SpA-related conditions. Results IL-17A did not induce a pro-inflammatory response in human LAD2 mast cells according to the canonical IL-17A signalling pathway. In SpA synovial tissue, the percentage of IL-17A-positive mast cells increased upon treatment with secukinumab. IL-17A-positive mast cells were also readily detectable in non-inflamed barrier tissues such as skin and gut. In non-inflamed dermis and gut submucosa, IL-17A-positive mast cells are the most prevalent IL-17A-positive cells in situ. Compared with non-inflamed tissues, both total mast cells and IL-17A-positive mast cells were increased in psoriatic skin dermis and in submucosa from inflammatory bowel disease gut. In contrast, the proportion of IL-17A-positive mast cells was strikingly lower in the inflamed compared with non-inflamed gut lamina propria. Conclusion IL-17A-positive mast cells are present across SpA target tissues and correlate inversely with inflammation, indicating that their IL-17A content can be regulated. Tissue-resident mast cells may act as IL-17A-loaded sentinel cells, which release IL-17A to amplify tissue inflammation. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

14. FCGR2A/CD32AandFCGR3A/CD16AVariants and EULAR Response to Tumor Necrosis Factor-α Blockers in Psoriatic Arthritis: A Longitudinal Study with 6 Months of Followup

Author

RAMÍREZ, JULIO, primary, FERNÁNDEZ-SUEIRO, JOSÉ LUIS, additional, LÓPEZ-MEJÍAS, RAQUEL, additional, MONTILLA, CARLOS, additional, ARIAS, MAITE, additional, MOLL, CONCEPCIÓN, additional, ALSINA, MERCÉ, additional, SANMARTI, RAIMON, additional, LOZANO, FRANCISCO, additional, and CAÑETE, JUAN D., additional

Published
2012
Full Text
View/download PDF

20. FCGR2A/CD32A and FCGR3A/CD16A Variants and EULAR Response to Tumor Necrosis Factor-α Blockers in Psoriatic Arthritis: A Longitudinal Study with 6 Months of Followup

Author

RAMÍREZ, JULIO, FERNÁNDEZ-SUEIRO, JOSÉ LUIS, LÓPEZ-MEJÍAS, RAQUEL, MONTILLA, CARLOS, ARIAS, MAITE, MOLL, CONCEPCIÓN, ALSINA, MERCÉ, SANMARTI, RAIMON, LOZANO, FRANCISCO, and CAÑETE, JUAN D.

Abstract

OBJECTIVE: The efficacy of antibody-based biological therapies currently used in psoriatic arthritis (PsA) depends not only on their blocking effect on the targeted molecule but also on their binding affinity to genetically defined variants of cell-surface Fc-γ receptors. Our objective was to assess the potential influence of functionally relevant FCGR2A/CD32A (H131R) and FCGR3A/CD16A (V158F) genetic polymorphisms on the EULAR response to tumor necrosis factor-α (TNF-α) blocker therapy in PsA. METHODS: In total 103 patients with PsA starting anti-TNF-α therapy were included. The efficacy of therapy was evaluated according to EULAR response criteria at 3 and 6 months. FCGR2A-R131H and FCGR3A-F158V polymorphisms were genotyped. Potential correlations between clinical response and the FCGR2A-R131H and FCGR3A-F158V polymorphisms were evaluated. RESULTS: EULAR response (moderate plus good) was 85.4% at 3 months and 87.4% at 6 months, while good EULAR response was 61.2% and 62.1%, respectively. More patients with high-affinity FCGR2A genotypes (homozygous or heterozygous combinations) achieved a EULAR response at 6 months compared to patients with the low-affinity genotype (RR; p = 0.034, adjusted comparison error rate < 0.025). This association was due mainly to the group of patients treated with etanercept. No correlation was found for the FCGR3A polymorphism. Similarly, no effect of C-reactive protein levels was observed. CONCLUSION: Our data indicate that FCGR2A polymorphism may influence the response to TNF-α blockers (namely etanercept) in PsA in a direction opposite to that previously found in patients with rheumatoid arthritis.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results